| Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial JV Gavilondo, F Hernández-Bernal, M Ayala-Ávila, AV De La Torre, ... Vaccine 32 (19), 2241-2250, 2014 | 56 | 2014 |
| Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates Y Morera, M Bequet-Romero, M Ayala, JC Velazco, PP Pérez, JS Alba, ... Vaccine 28 (19), 3453-3461, 2010 | 48 | 2010 |
| Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants Y Morera, M Bequet-Romero, M Ayala, H Lamdán, EM Agger, P Andersen, ... Angiogenesis 11, 381-393, 2008 | 48 | 2008 |
| In vitro assembly into virus-like particles is an intrinsic quality of Pichia pastoris derived HCV core protein N Acosta-Rivero, A Rodriguez, A Musacchio, V Falcón, VM Suarez, ... Biochemical and biophysical research communications 325 (1), 68-74, 2004 | 44 | 2004 |
| CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors M Bequet-Romero, Y Morera, M Ayala-Ávila, J Ancizar, Y Soria, A Blanco, ... Vaccine 30 (10), 1790-1799, 2012 | 36 | 2012 |
| Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine Y Morera, J Sánchez, M Bequet-Romero, KH Selman-Housein, ... Vaccine 35 (28), 3582-3590, 2017 | 30 | 2017 |
| Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates Y Morera, M Bequet-Romero, M Ayala, PP Pérez, J Castro, J Sánchez, ... Vaccine 30 (2), 368-377, 2012 | 30 | 2012 |
| Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S‐transferase fusion protein Y Morera, H Lamdan, M Bequet, M Ayala, G Rojas, Y Muñoz, ... Biotechnology and applied biochemistry 44 (1), 45-53, 2006 | 19 | 2006 |
| Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model Y Morera, R González, H Lamdan, L Pérez, Y González, J Agüero, ... Experimental eye research 122, 102-109, 2014 | 15 | 2014 |
| Isolation of a novel neutralizing antibody fragment against human vascular endothelial growth factor from a phage-displayed human antibody repertoire using an epitope … H Lamdan, M Ayala, G Rojas, Y Munoz, Y Morera, O Guirola, G Chinea, ... Journal of biotechnology 151 (2), 166-174, 2011 | 13 | 2011 |
| Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two … J Sánchez Ramírez, Y Morera Díaz, M Bequet-Romero, ... BMC immunology 18, 1-20, 2017 | 12 | 2017 |
| Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate L Perez Sanchez, Y Morera Diaz, M Bequet-Romero, ... Human Vaccines & Immunotherapeutics 11 (8), 2030-2037, 2015 | 11 | 2015 |
| Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? J Sánchez Ramírez, M Bequet-Romero, Y Morera Díaz, ... BMC research notes 12, 1-5, 2019 | 10 | 2019 |
| Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: from bench to bedside Y Morera-Díaz, JV Gavilondo, M Bequet-Romero, JS Ramírez, ... Seminars in oncology 45 (1-2), 68-74, 2018 | 9 | 2018 |
| Obtaining biologically active IL-15 in Escherichia coli A Santos, Y Morera, M Araña, J Ferrero, A Moro, J García, E Sanz, ... Biotecnol Apl 17 (4), 221-4, 2000 | 9 | 2000 |
| Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates Y Rodríguez-Álvarez, Y Morera-Díaz, H Gerónimo-Pérez, ... BMC immunology 17, 1-14, 2016 | 8 | 2016 |
| Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF J Sánchez Ramírez, Y Morera Díaz, A Musacchio Lasa, ... Journal of Immunoassay and Immunochemistry 37 (6), 636-658, 2016 | 8 | 2016 |
| Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program J Sánchez Ramírez, Y Morera Díaz, M Bequet-Romero, ... BMC immunology 21, 1-17, 2020 | 7 | 2020 |
| Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors JS Ramírez, M Bequet-Romero, YM Díaz, F Hernández-Bernal, ... Heliyon 4 (11), 2018 | 4 | 2018 |
| Clinical benefits in patients with advanced solid tumors after long-term immunization with a VEGF therapeutic vaccine KH Selman-Housein, A de la Torre, F Hernández-Bernal, Y Martin, ... Open J Clin Med Case Rep 3 (2), 2017 | 4 | 2017 |
